TIGIT Inhibitors Clinical Trials, Competitive Landscape, Latest FDA, EMA and PDMA Approvals, Therapies and Treatment Options by DelveInsight

November 28 22:07 2022
TIGIT Inhibitors Clinical Trials, Competitive Landscape, Latest FDA, EMA and PDMA Approvals, Therapies and Treatment Options by DelveInsight
TIGIT Inhibitors Competitive Landscape
TIGIT Inhibitors pipeline constitutes 18+ key companies continuously working towards developing 20+ TIGIT Inhibitors treatment therapies, analyzes DelveInsight

T cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed on lymphocytes that was recently propelled under the spotlight as a major emerging target in cancer immunotherapy. TIGIT interacts with CD155 expressed on antigen‐presenting cells or tumor cells to down‐regulate T cell and natural killer (NK) cell functions. TIGIT has emerged as a key inhibitor of anti‐tumor responses that can hinder multiple steps of the cancer immunity cycle.

 

DelveInsights, “TIGIT Inhibitors Competitive landscape, 2022” report provides comprehensive insights about 18+ companies and TIGIT Inhibitors drugs in TIGIT inhibitors Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

 

To know more about the TIGIT Inhibitors Competitive landscape report, click here: TIGIT Inhibitors Competitive Assessment

 

Key Takeaways from the TIGIT Inhibitors Competitive landscape report:

  • Leading TIGIT Inhibitors Companies working in the market are Merck Sharp & Dohme, Bristol-Myers Squibb, BeiGene, Arcus Biosciences, iTeos Therapeutics, Mereo BioPharma, Phio Pharmaceuticals, Bio-Thera Solutions, Compugen.
  • Key TIGIT Inhibitors therapies in various stages of development include Ociperlimab+ Tislelizumab, MK-7684A, Domvanalimab+ Zimberelimab, BMS 986207, BAT-6005, AGEN 1777+ PD-1 Inhibitor, PH 804, TSRF-786-C and Others.
  • In December 2021, Bio-Thera Solutions a commercial-stage pharmaceutical company announced that dosing has begun in Phase I clinical study to compare the pharmacokinetics and safety of BAT6005, a monoclonal antibody targeting TIGIT in cancer patient volunteers.

 

DelveInsight’s TIGIT Inhibitors Report covers around 200+ products under different phases of clinical development like

  • Assessment by TIGIT Inhibitors Product Type
  • Assessment by Stage and Product Type of TIGIT Inhibitors
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration of TIGIT Inhibitors
  • Assessment by TIGIT Inhibitors Molecule Type
  • Assessment by Stage and Molecule Type of TIGIT Inhibitors

 

Emerging TIGIT Inhibitors Drugs Under Different Phases of Clinical Development Include:

Some of the TIGIT Inhibitors therapies are Ociperlimab, MK-7684A (pembrolizumab/vibostolimab), BMS 986207, BAT-6005 and Many Others.

 

Further TIGIT Inhibitors product details are provided in the report. Download the TIGIT Inhibitors Pipeline report to learn more about the emerging TIGIT Inhibitors therapies at: TIGIT Inhibitors Clinical Trials and Developments

 

Drug/Drug Combination

Company Name

Phase

Indication

Ociperlimab +  Tislelizumab

BeiGene

Phase III

Non-small Cell Lung Cancer

MK-7684A (pembrolizumab/vibostolimab)

Merck Sharp & Dohme

Phase III

Non-Small-Cell Lung Carcinoma

Domvanalimab +  Zimberelimab 

Arcus Biosciences

Phase III

Non-Small Cell Lung Cancer

BMS 986207

Bristol-Myers Squibb

Phase II

Non-Small Cell Lung Cancer

BAT-6005

Bio-Thera Solutions

Phase I

Locally Advanced or Metastatic Solid Tumors

AGEN 1777 +  PD-1 Inhibitor

Agenus

Phase I

Advanced Solid Tumors

PH 804

Phio Pharmaceuticals

Preclinical

Solid Tumors

TSRF-786-C

Tasrif Pharmaceutical

Preclinical

Cancer

 

 Key companies in the TIGIT Inhibitors Therapeutics Market:

Some of the TIGIT Inhibitors Companies working in the market are Merck Sharp & Dohme, Bristol-Myers Squibb, BeiGene, Arcus Biosciences, iTeos Therapeutics, Mereo BioPharma, Phio Pharmaceuticals, Bio-Thera Solutions, Compugen.

 

Request for Sample PDF Report to know in detail about the recent developments and advancements in TIGIT Inhibitors clinical trials – TIGIT Inhibitors Competitive Landscape

 

Table of Content (TOC)

1. TIGIT Inhibitors Pipeline Report Introduction

2. TIGIT Inhibitors Pipeline Report Executive Summary

3. TIGIT Inhibitors Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. TIGIT Inhibitors Clinical Trial Therapeutics

6. TIGIT Inhibitors Pipeline: Late Stage Products (Pre-registration)

7. TIGIT Inhibitors Pipeline: Late Stage Products (Phase III)

8. TIGIT Inhibitors Pipeline: Mid Stage Products (Phase II)

9. TIGIT Inhibitors Pipeline: Early Stage Products (Phase I)

10. TIGIT Inhibitors Pipeline Therapeutic Assessment

11. Inactive Products in the TIGIT Inhibitors Pipeline

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Key TIGIT Inhibitors Companies

14. Key Products in the TIGIT Inhibitors Pipeline

15. Unmet Needs

16. TIGIT Inhibitors Market Drivers and Barriers

17. Future Perspectives and Conclusion

18. Analyst Views

19. Appendix

 

Download Sample PDF Report to know more about @ TIGIT Inhibitors Drugs and Therapies

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

  Categories: